Project Grant R01CA311185
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $683K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $402,011 Project Grant to The University of Texas Southwestern Medical Center, effective May 1, 2026 through April 30, 2031, under the Cancer Biology Research program (CFDA 93.396). This research grant funds a five-year investigative study entitled "Control of T-Cell Stemness and T-Cell Exhaustion by KEAP1-NRF2 Axis," which will be conducted at the institution's Dallas, Texas campus. The research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $639,514 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The University of Texas Southwestern Medical Center, effective June 1, 2026, through May 31, 2031. This five-year research initiative focuses on characterizing the mechanistic basis of NVL (Nuclear VCP-Like) inhibition by benzothiazepinone compounds—specifically MM17—as a novel non-genotoxic chemotherapy strategy. The research delivers...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Texas at Austin a $2.59 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2029. The award supports research to develop a novel cancer immunotherapy approach targeting immune-excluded or "cold" tumors that typically demonstrate poor response to immune checkpoint therapy. The project focuses on demonstrating that degradation of...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $501,803 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective June 1, 2026, through May 31, 2031. This research project focuses on decoding the stromal microenvironment of pancreatic ductal adenocarcinoma (PDAC) by elucidating the role of antigen-presenting cancer-associated fibroblasts (APCAFs) in tumor progression and...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $498,732 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on July 1, 2026, with a completion date of June 30, 2031. This five-year research initiative investigates the role of low-density lipoprotein (LDL) uptake in tumor immunity and immunotherapy efficacy, specifically examining how systemic LDL availability influences CD8+ T...
- Summary of Federal Project Grant Award The University of Texas Southwestern Medical Center received a $687,594 project grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2026, through June 30, 2031. This award supports fundamental research on brain metastasis organotropism and therapy response in small cell lung cancer (SCLC), addressing the critical clinical need for more effective and less toxic treatment alternatives to...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas Southwestern Medical Center a $688,012 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 1, 2026, with a completion date of May 31, 2031. This award supports the development of novel RPS23 (ribosomal protein S23) inhibitors for the treatment of acute myeloid leukemia (AML). The research leverages an integrated platform combining high-throughput phenotypic screening with rapid...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $426,828 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective June 1, 2026, through May 31, 2028. The grant supports research targeting epigenetic vulnerabilities in osteosarcoma to enhance immunotherapy outcomes in pediatric patients. The research integrates two complementary approaches: (1) development of novel...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $376,886 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) for the period July 1, 2026 through June 30, 2029. The award supports the development of novel small-molecule inhibitors targeting Site-One Protease (S1P) to prevent and treat cancers, particularly clear cell renal cell carcinoma and hepatocellular carcinoma. The research builds...
- Federal Project Grant Award Summary The University of North Texas received a $148,500 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective September 5, 2025, through August 31, 2027. The research evaluates the role of extracellular vesicles (EVs) in tumor microenvironment modulation, with a specific focus on identifying mechanisms of T cell suppression in non-small cell lung cancer (NSCLC) and other immune-cold tumors. The...